These findings underscore the potential significance of high NKAIN1 protein expression in gastric cancer tissues during clinical diagnosis and treatment, suggesting that immune checkpoint inhibitors targeting CTLA-4 or PD-1/PD-L1 could be considered to improve therapeutic outcomes. This evidence concerns the gene CD274 and gastric cancer.